Genes upregulated in prostate cancer reactive stroma promote prostate cancer progression in vivo

Clinical Cancer Research

Volumn 20, Issue 1, 2014, Pages 100-109

  Dakhova, Olga ^a   Rowley, David ^a   Ittmann, Michael ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; SHORT HAIRPIN RNA; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR GLI2; VASCULOTROPIN A; WNT10B PROTEIN;

ABCB1 GENE; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANPEP GENE; APOPTOSIS; ARTICLE; BDNF GENE; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; CSF2 GENE; DOWN REGULATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; KAT2B GENE; LIF GENE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OCT4 GENE; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RUNX2 GENE; STEM CELL; STROMA CELL; THY1 GENE; UPREGULATION; VEGFA GENE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PROSTATE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; STROMAL CELLS; TUMOR BURDEN; TUMOR MICROENVIRONMENT; UP-REGULATION; WNT PROTEINS;

EID: 84892164626     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1184     Document Type: Article

References (33)

1. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol 2001;166:2472-83.
2. Chung LW, Baseman A, Assikis V, Zhau HE. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 2005;173:10-20.
3. Ayala G, Tuxhorn JA, Wheeler TM, Frolov A, Scardino PT, Ohori M, et al. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res 2003;9:4792-801.
4. Yanagisawa N, Li R, Rowley D, Liu H, Kadmon D, Miles BJ, et al. Reprint of: Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrencefree survival in patients after radical prostatectomy. Hum Pathol 2008;39:282-91.
5. Ayala GE, Muezzinoglu B, Hammerich KH, Frolov A, Liu H, Scardino PT, et al. Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. Am J Pathol 2011;178:79-87.
6. Dakhova O, Ozen M, Creighton CJ, Li R, Ayala G, Rowley D, et al. Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res 2009;15:3979-89.
7. Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res 2002; 62:3298-307.
8. Schauer IG, Ressler SJ, Tuxhorn JA, Dang TD, Rowley DR. Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology 2008;72:205-13.
9. Yu W, Feng S, Dakhova O, Creighton CJ, Cai Y, Wang J, et al. FGFR-4 Arg(3)(8)(8) enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling. Clin Cancer Res 2011;17:4355-66.
10. Shao L, Tekedereli I, Wang J, Yuca E, Tsang S, Sood A, et al. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res 2012;18:6648-57.
11. Feng S, Shao L, Yu W, Gavine P, Ittmann M. Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression. Clin Cancer Res 2012;18:3880-8.
12. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002; 8:2912-23.
13. Crea F, Duhagon Serrat MA, Hurt EM, Thomas SB, Danesi R, Farrar WL. BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer. Int J Cancer 2011;128:1946-54.
14. Stevens JR, Miranda-Carboni GA, Singer MA, Brugger SM, Lyons KM, Lane TF. Wnt10b deficiency results in age-dependent loss of bone mass and progressive reduction of mesenchymal progenitor cells. J Bone Miner Res 2010;25:2138-47.
15. Cawthorn WP, Bree AJ, Yao Y, Du B, Hemati N, Martinez-Santibanez G, et al. Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a beta-catenin-dependent mechanism. Bone 2012;50:477-89.
16. Siddique HR, Saleem M. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells 2012;30:372-8.
17. van Leenders GJ, Dukers D, Hessels D, van den Kieboom SW, Hulsbergen CA, Witjes JA, et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 2007;52:455-63.
18. Ayala GE, Dai H, Ittmann M, Li R, Powell M, Frolov A, et al. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res 2004;64:6082-90.
19. Ayala GE, Dai H, Powell M, Li R, Ding Y, Wheeler TM, et al. Cancerrelated axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res 2008;14:7593-603.
20. Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ, et al. Autonomic nerve development contributes to prostate cancer progression. Science 2013;341:1236361.
21. Li X, Placencio V, Iturregui JM, Uwamariya C, Sharif-Afshar AR, Koyama T, et al. Prostate tumor progression ismediated by a paracrine TGF-beta/Wnt3a signaling axis. Oncogene 2008;27:7118-30.
22. Richardson AM, Woodson K, Wang Y, Rodriguez-Canales J, Erickson HS, Tangrea MA, et al. Global expression analysis of prostate cancerassociated stroma and epithelia. Diagn Mol Pathol 2007;16:189-97.
23. Kim C, Choi J, Park H, Park Y, Park J, Park T, et al. Global analysis of microarray data reveals intrinsic properties in gene expression and tissue selectivity. Bioinformatics 2010;26:1723-30.
24. Klee EW, Bondar OP, Goodmanson MK, Dyer RB, Erdogan S, Bergstralh EJ, et al. Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and blood. Clin Chem 2012; 58:599-609.
25. Untergasser G, Gander R, Lilg C, Lepperdinger G, Plas E, Berger P. Profiling molecular targets of TGF-beta1 in prostate fibroblastto-myofibroblast transdifferentiation. Mech Ageing Dev 2005;126:59-69.
26. Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, Rowley DR. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res 2005; 65:8887-95.
27. Simak R, Capodieci P, Cohen DW, Fair WR, Scher H, Melamed J, et al. Expression of c-kit and kit-ligand in benign and malignant prostatic tissues. Histol Histopathol 2000;15:365-74.
28. Feng S, Dakhova O, Creighton CJ, Ittmann M. Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res 2013;73:2551-62.
29. Hou X, Appleby N, Fuentes T, Longo LD, Bailey LL, Hasaniya N, et al. Isolation, characterization, and spatial distribution of cardiac progenitor cells in the sheep heart. J Clin Exp Cardiolog 2012;S6:pii:004.
30. Zhang J, Lipinski R, Shaw A, Gipp J, Bushman W. Lack of demonstrable autocrine hedgehog signaling in human prostate cancer cell lines. J Urol 2007;177:1179-85.
31. Shaw A, Gipp J, Bushman W. The Sonic Hedgehog pathway stimulates prostate tumor growth by paracrine signaling and recapitulates embryonic gene expression in tumor myofibroblasts. Oncogene 2009;28:4480-90.
32. Lauth M, Toftgard R. Non-canonical activation of GLI transcription factors: implications for targeted anti-cancer therapy. Cell Cycle 2007; 6:2458-63.
33. Franco OE, Jiang M, Strand DW, Peacock J, Fernandez S, Jackson RS II, et al. Altered TGF-beta signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res 2011;71:1272-81.